Previous Close | 7.03 |
1-Year Change | 36.77% |
6-Months Change | 11.94% |
3-Months Change | -10.56% |
Moving Avg (50d) | 7.6978 |
Moving Avg (200d) | 6.5271 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 1.33B |
Beta (3-Years) | 1.24 |
Revenue Growth (ttm) | 33.18% |
Net Profit Margin (ttm) | -74.43% |
Return On Assets (ttm) | -45.2% |
EPS (ttm) | -1.25 |
PE Ratio (ttm) | -5.62 |
Dividend Yield | % |
Asset Description: | BioCryst Pharmaceuticals, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-11-20 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
7.154 | 6.935 | 6.789 | 6.57 | 6.205 | 5.84 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China. Wikipedia